Skip to main content

Table 2 Inclusion and exclusion study criteria

From: Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in western Kenya compared to placebo: study protocol for a cluster-randomized double-blinded control trial (the AEGIS program)

Inclusion criteria Exclusion criteria
Children aged 6 months to < 10 years Children <  6 months or ≥ 10 years
Hb >  5 mg/dl Hb ≤ 5 mg/dL, or Hb < 6 mg/dL with signs of clinical decompensation
Sleeps in cluster > 90% of nights during any given month Sleeps in cluster < 90% of nights during any given month
No plans for extended travel (> 1 month) outside of home during study Plans for extended travel (> 1 month) outside of home during study
Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
Provision of informed consent form (ICF) signed by the parent(s) or guardian No provision of ICF signed by the parent(s) or guardian
Children not on regular malaria prophylaxis*** Children on regular malaria prophylaxis***
Willingness to take Artemether-Lumefantrine (AL) and no history of hypersensitivity to AL Unwillingness or refusal to take AL and history of AL hypersensitivity
  1. *** Malaria prophylaxis medicines: Mefloquine, Atavaquone/Proguanil (Malarone), Doxycycline, Sulfadoxine-Pyrimethamine (Fansidar), Amodiaquine, and Co-trimoxazole (Septrin)